Pfizer (NYSE:PFE) Shares Climb 2.4% – Still a Buy?

Pfizer Inc. (NYSE:PFE) rose 2.4% on Tuesday. The company traded as high as $30.25 and last traded at $30.1370. 34,224,934 shares traded hands during mid-day trading, a decline of 14% from the average session volume of 40,024,027 shares. The stock had previously closed at $29.44.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Healthcare-sector rotation supports PFE. Biotech and pharmaceutical stocks have shown relative strength during the technology and AI sell-off. Pfizer was identified as one of the sector’s standout performers, with investors attracted to its defensive revenue base, value profile and dividend income. Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs
• Positive Sentiment: Pfizer’s turnaround narrative is gaining traction. Coverage highlighted the company’s recent oncology approvals and multibillion-dollar cancer collaboration as evidence that Pfizer is rebuilding growth beyond its pandemic-era products. Its latest reported quarter also exceeded analyst expectations for earnings and revenue, providing additional support for the stock. What Pfizer Bulls Got Right
• Neutral Sentiment: Pipeline updates remain under review. Pfizer completed its Phase 2 MAGNETISMM-3 study of elranatamab and announced an ongoing study examining etrasimod exposure in breastfeeding women. These updates may support long-term pipeline visibility, but the reports did not provide a clear, immediate earnings or regulatory catalyst. Pfizer’s Elranatamab Trial Update
• Neutral Sentiment: Analyst sentiment is cautious. Wells Fargo and RBC Capital maintained Hold ratings, indicating that investors may want more evidence that Pfizer’s oncology strategy can offset declining COVID-related revenue and other portfolio pressures. Pfizer Gets a Hold from Wells Fargo
• Negative Sentiment: Dividend sustainability remains a risk. Commentary questioned whether Pfizer’s substantial dividend is fully supported by cash flow, while the company’s dividend freeze could limit income-investor enthusiasm if financial performance weakens. Pfizer’s Dividend Freeze Raises a Bigger Question About Its Cash Flow

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of analyst reports. HSBC increased their price objective on Pfizer from $28.00 to $30.00 and gave the company a “hold” rating in a research note on Thursday, September 10th. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Saturday, October 10th. Bank of America decreased their price target on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. Cantor Fitzgerald lifted their price target on shares of Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a report on Thursday, October 8th. Finally, Guggenheim reiterated a “buy” rating on shares of Pfizer in a report on Tuesday, October 13th. Five analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $28.72.

Pfizer Trading Up 2.4%

The company has a market cap of $171.77 billion, a PE ratio of 39.65, a price-to-earnings-growth ratio of 2.01 and a beta of 0.32. The business has a 50 day simple moving average of $28.05 and a two-hundred day simple moving average of $26.57. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. The business had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. The business’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 7th. Stockholders of record on Friday, November 6th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, November 6th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 5.7%. Pfizer’s dividend payout ratio is currently 226.32%.

Institutional Investors Weigh In On Pfizer

Several hedge funds have recently modified their holdings of PFE. BlackRock Inc. raised its position in shares of Pfizer by 6.3% in the 2nd quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock worth $12,754,464,000 after buying an additional 31,412,883 shares during the period. State Street Corp grew its position in Pfizer by 1.8% during the second quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company’s stock valued at $7,394,749,000 after acquiring an additional 5,501,032 shares during the period. Bank of New York Mellon Corp increased its stake in Pfizer by 11.1% during the first quarter. Bank of New York Mellon Corp now owns 53,879,900 shares of the biopharmaceutical company’s stock worth $1,512,948,000 after acquiring an additional 5,364,929 shares during the last quarter. Bank of America Corp DE acquired a new stake in Pfizer during the second quarter worth about $1,049,602,000. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Pfizer by 0.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 36,422,799 shares of the biopharmaceutical company’s stock worth $1,022,606,000 after purchasing an additional 293,029 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

About Pfizer

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.